Immune Checkpoint Articles & Analysis: Older
22 articles found
Immunomodulatory Therapies The concept of harnessing the body’s immune response against viral infections has gained traction over the years. Immunomodulatory therapies aim to enhance the immune system’s ability to recognize and eliminate viral pathogens. In 2024, the development of monoclonal antibodies and immune ...
Immune receptors, which are protein molecules expressed on the membrane of immune cells, play a key role in regulating immune responses. ...
Overall, the integration of multi-omics data and advancements in immune-oncology plays a significant part in developing precise treatments for brain tumors2. Key techniques include multi-omics profiling, immune checkpoint blockers (ICBs), RNA-sequencing (RNA-Seq), single-cell analysis, imaging mass cytometry (IMC), and multiplexed ion beam ...
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...
ByTempus
In addition, Nbs can resist the denaturing effects of proteases, extreme pH, and hydrophobic agents.Concatenated into multi-specific or multivalent configurations: Compared with mAbs, Nbs are smaller in size, which is conducive to tandem with a variety of antibody domains with different functions for the delivery of multi-functional drugs, enhancing affinity while avoiding rapid renal clearance ...
Its primary function revolves around converting extracellular ATP into immunosuppressive adenosine, working in tandem with CD39 within normal tissues to curtail excessive immune reactions. However, this mechanism is often hijacked by tumors, utilizing CD73 to foster an adenosinergic process that shields them from immune assaults. ...
Cotton, A.D., et al., Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1, J. Am. Chem. Soc., 2021, 143, 593-598. 5. ...
Mechanism of Vaccine Adjuvants Vaccine excipients, including adjuvants, are added to vaccine formulations to enhance the immune response by providing necessary signals to the immune system. Adjuvants can stimulate the innate immune system, improving the recognition of antigens and promoting a more robust adaptive immune response. ...
So which cells are best used for immunotherapies? Immune Checkpoint Inhibitors Controlling the strength and amplitude of an immune response is a critical feature of a healthy immune system. ...
Cytokines-mediated signaling is a primary way of immune system communication. The common gamma-chain family of cytokines is a set of six cytokines that signal through the common cytokine γ chain receptor (γc/CD132/IL2RG). These cytokines include IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Besides the IL-2RG receptor subunit, the γc family cytokine receptors include IL-2RB ...
(“Aesther”) (NASDAQ: AEHA) announced today the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%. ...
Pembrolizumab is a class of immunotherapy drugs called immune checkpoint inhibitors (ICIs), while ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, a class of drugs that block the enzyme drug. ...
The study, published in Cancer Cell, provides evidence for the concept of combining immune checkpoint blockers and cytokine blockers to selectively inhibit inflammatory autoimmune responses. ...
Opdualag therapy is a fixed-dose combination of Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma, making LAG-3 the third immune checkpoint in the clinic after PD-1 and CTLA-4. Lymphocyte-activation gene 3 (LAG-3), also known as CD233, is a type I ...
The most frequent pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic malignancies. Immune checkpoint inhibitors have had exceptional success in many cancers and have even transformed the cancer therapy landscape, yet this treatment has not benefitted pancreatic cancer patients. ...
Background Tumor immunotherapies compose immune checkpoint inhibitors, therapeutic antibodies, tumor vaccines, cellular therapies, and so on. However, each has its own set of issues, such as the fact that CAR-T therapy is an individual therapy that is costly; immune checkpoint inhibitors are highly effective, but only in some ...
The advent of immune checkpoint inhibitors (ICI) has improved the overall survival of patients with a variety of malignancies. ...
In contrast, γδ T cells, expressing γδ TCR, are effector cells in the innate immune system, which function in an MHC-unrestricted manner, making them ideal mediators for cancer immunotherapy. ...
Over time, genetic research have recognized a number of genetic danger variants related to neurodegenerative problems and helped reveal new organic pathways and genes of curiosity. Nevertheless, genetic danger variants generally reside in non-coding areas and should regulate distant genes reasonably than the closest gene, in addition to a gene’s interplay companions in organic networks. ...
Drugs called immune checkpoint inhibitors have provided life-saving benefits to more and more people suffering from melanoma, lung cancer, bladder cancer, and many other types of cancer. ...